Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 08, 2026 16:05 ET | Source: Candel Therapeutics

Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NEEDHAM, Mass., July 08, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal...
July 01, 2026 16:05 ET | Source: Candel Therapeutics

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEEDHAM, Mass., July 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal...
May 14, 2026 09:37 ET | Source: Research and Markets

CD40 Agonists and CD40/L Antagonists Pipeline Competitor Analysis Report 2026: Active R&D Programs by R&D Phase and Profile of Agonists and Antagonists by Drug Modality

Dublin, May 14, 2026 (GLOBE NEWSWIRE) -- The "Pipeline of CD40 Agonists and CD40/L Antagonists" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence report about...
May 01, 2026 16:05 ET | Source: Candel Therapeutics

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEEDHAM, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal...
April 21, 2026 06:39 ET | Source: Research and Markets

Immuno-Oncology Drugs Market Opportunity Analysis and Forecast Report 2026-2035: Merck & Co. Remains a Dominant Force, Supported by the Commercial Success of Keytruda

Dublin, April 21, 2026 (GLOBE NEWSWIRE) -- The "Immuno-Oncology Drugs Market Size, Industry Dynamics, Opportunity Analysis and Forecast 2026-2035" report has been added to ResearchAndMarkets.com's...
April 21, 2026 04:13 ET | Source: Research and Markets

Trispecific Antibodies Market Landscape Report 2026: Opportunity and Proprietary Insights - 90 Trispecific Antibodies by Company, Country, Indication & Phase

Dublin, April 21, 2026 (GLOBE NEWSWIRE) -- The "Trispecific Antibodies Market Opportunity, Proprietary Technologies & Clinical Trials Insight 2026" report has been added to ...
February 03, 2026 07:51 ET | Source: Research and Markets

Cancer Immunotherapy Research Report 2026: Market Forecasts 2025-2029 for Immuno-Oncology Therapeutics by Therapy, Cancer and Customer with Executive and Consultant Guides

Dublin, Feb. 03, 2026 (GLOBE NEWSWIRE) -- The "Cancer Immunotherapy Market 2025-2029 - Forecasts for Immuno-Oncology Therapeutics by Therapy, Cancer and Customer, with Executive and Consultant...
December 10, 2025 09:15 ET | Source: Research and Markets

China Leads Therapeutic Access with 74 Approved Immuno-Oncology Agents

Dublin, Dec. 10, 2025 (GLOBE NEWSWIRE) -- The "Strategic Intelligence: Immuno-oncology (2025)" has been added to ResearchAndMarkets.com's offering. The latest report delves into the dynamic...
December 02, 2025 04:10 ET | Source: Research and Markets

Abemaciclib Research Report 2025: Eli Lilly and Company Dominates the $1.6 Billion Market - Long-term Forecasts to 2029 and 2034

Dublin, Dec. 02, 2025 (GLOBE NEWSWIRE) -- The "Abemaciclib Market Report 2025" report has been added to ResearchAndMarkets.com's offering.The abemaciclib market size has grown rapidly in recent...
November 27, 2025 08:58 ET | Source: Research and Markets

CD40 Agonists and CD40/L Antagonists Pipeline and Competitive Intelligence Report 2025

Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The "Pipeline of CD40 Agonists and CD40/L Antagonists" report has been added to ResearchAndMarkets.com's offering.This competitive intelligence report...